TheraRadar
Data updated: May 26, 2026

IMPEKLO (clobetasol propionate)

Immunology Approved 2020-05-19
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Discontinued
First Approved
2020-05-19
Routes
TOPICAL
Dosage Forms
LOTION

Companies

PHARMOBEDIENT
Active Ingredient: CLOBETASOL PROPIONATE

IMPEKLO Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2020 to 2020
May 2020 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer
FDA Letter Label

What IMPEKLO Treats

1 FDA approvals

Originally approved for its first indication in 2020 .

  • Other (1)
📋

Clinical Trial Registry

12 trials
Trial Sponsor ID Phase Status Title
NCT02368886 results posted RU021407I NCI-2015-00011, RU021407I Ph 2 completed Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT05364515 PRGF BTIIMD-01-EC/217LIQUEN Ph 3 withdrawn Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva
NCT04364555 LIKLO-1 Ph 2, Ph 3 active not recruiting Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
NCT05724446 CLOSE-3 CLOBOF3-17IA03 Ph 3 recruiting Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
NCT04246801 CLOSE-1 results posted CLOBOF3-16IA01 Ph 3 completed Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
NCT04249076 CLOSE-2 results posted CLOBOF3-16IA02 Ph 3 completed Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
NCT03592342 DT-001-R-004 Ph 2 completed Intra-oral Treatment of OLP With Rivelin®-CLO Patches
NCT03535233 AA22 Ph 4 completed Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata
NCT02936492 17014 Ph 1 terminated BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study
NCT01381445 113435 Ph 1 completed A Study Assessing GW870086's Potential to Cause Skin Thinning
NCT02940002 17012 2016-000962-47 Ph 1 completed BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test
NCT00828464 results posted U0280-401 Ph 4 completed Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IMPEKLO FDA Label Details

Track IMPEKLO with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA213691 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.